TSE:4516
TSE:4516Pharmaceuticals

Nippon Shinyaku (TSE:4516): Exploring Valuation Following Recent Share Price Fluctuations

Nippon Shinyaku (TSE:4516) stock has seen mixed movement recently, with a slight uptick over the past week but declines over the past month and year. Valuation-focused investors may be assessing what is driving these swings. See our latest analysis for Nippon Shinyaku. While Nippon Shinyaku's share price has staged a modest recovery in the past week, momentum remains muted compared to its longer-term performance. The latest 1-year total shareholder return of -17.2% underscores how sentiment...
TSE:4631
TSE:4631Chemicals

DIC (TSE:4631): Evaluating Valuation After Recent Share Price Gains

DIC (TSE:4631) has drawn interest lately as its stock quietly moved higher, gaining about 18% over the past 3 months. Investors are now taking a closer look at its recent performance, searching for clues about potential future direction. See our latest analysis for DIC. After a strong three-month run, DIC’s momentum shows signs of sticking around. The latest 12-month total shareholder return sits at an impressive 15.4%, and longer-term holders have seen a 66.6% total return over five years...
TSE:8058
TSE:8058Trade Distributors

Assessing Mitsubishi’s Value After New Strategic Moves and a 40.5% Annual Gain

Thinking about the true value behind Mitsubishi’s stock? You’re not alone, especially with all the chatter around its potential these days. While the past week saw Mitsubishi slip by 2.0%, the stock is still up an eye-catching 40.5% so far this year and has soared 420.6% over the past five years. This is fueling plenty of investor curiosity. Much of the interest lately has been sparked by reports of Mitsubishi’s new strategic ventures in renewable energy and overseas expansion. The coverage...
TSE:9434
TSE:9434Wireless Telecom

SoftBank (TSE:9434): Exploring Current Valuation After Recent Share Price Uptick

SoftBank (TSE:9434) shares ticked slightly higher in today's trading, catching investor attention after recent price moves. With the stock showing a modest gain, some are curious about whether this uptick could signal broader momentum in the future. See our latest analysis for SoftBank. SoftBank’s shares have edged higher lately, drawing renewed optimism as investors weigh both recent market swings and last year’s steady uptrend. While momentum has cooled over the past quarter, long-term...
TSE:7974
TSE:7974Entertainment

Nintendo (TSE:7974): Assessing Valuation Following a Strong Share Price Run

Nintendo (TSE:7974) shares have seen some movement lately, sparking conversation about what could be driving current sentiment. Investors are taking a closer look at recent trends, particularly the company’s performance over the past month. See our latest analysis for Nintendo. While Nintendo’s share price has been climbing, up nearly 10% in the past month and delivering an impressive 53% return year-to-date, its momentum stands out even more in the long term with a 72% total shareholder...
TSE:6701
TSE:6701IT

NEC (TSE:6701): Is the Tech Giant Trading Above Its True Value?

NEC (TSE:6701) has caught the market’s attention lately, as its share price has shown mixed moves over the past month. Investors are curious about how recent trends could impact the outlook for this established tech brand. See our latest analysis for NEC. NEC’s share price has climbed 103% year-to-date, with momentum building especially over the past month as risk appetite for tech plays grows. Looking at a longer timeframe, total shareholder return over the last three years stands at a...
TSE:4536
TSE:4536Pharmaceuticals

MHRA Approval of Ryjunea® Could Be a Game Changer for Santen Pharmaceutical (TSE:4536)

In the past week, Santen Pharmaceutical announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Ryjunea® (low-dose atropine 0.1 mg/ml) as the first licensed treatment to slow the progression of myopia in children, following earlier European Commission approval and launches in Europe. This milestone offers Santen a new opportunity to address the rising prevalence of childhood myopia in the UK and further strengthens its international presence in paediatric...
TSE:9684
TSE:9684Entertainment

Square Enix (TSE:9684) Considers Extraordinary Loss Amid Forecast Revision Is Its Turnaround Strategy at a Crossroads?

Square Enix Holdings announced that its board met on November 6, 2025, to consider recording an extraordinary loss for the six-month period ended September 30, 2025, and to revise its consolidated financial forecast for the fiscal year ending March 31, 2026. This disclosure signals ongoing financial uncertainties for the company, even as it continues to launch high-profile titles such as the recent DRAGON QUEST I & II HD-2D Remake. We’ll explore how the anticipated extraordinary loss and the...
TSE:8113
TSE:8113Household Products

Unicharm (TSE:8113): Assessing Valuation After 9-Month Profit Rises Despite Falling Sales

Unicharm (TSE:8113) just released its financial results for the first nine months of 2025, reporting a 4% decline in sales and lower core operating income. The company still managed a modest rise in profit to shareholders. See our latest analysis for Unicharm. Unicharm’s share price has staged a modest rebound over the past week, rising nearly 5 percent, following its latest earnings update. However, the picture remains tough for long-term shareholders. The one-year total shareholder return...